Allarity Therapeutics, Inc. (ALLR) stock
ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.87+0.03 (+3.69%)
Close on Nov 18, 2026Market cap $13.87MP/E –Yield –
Allarity Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Allarity Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$10.80M. For fiscal 2025 it was -$12.61M. The highest annual figure on record is -$8.32M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.61M | – |
| FY2024 | Dec 31, 2024 | -$27.24M | – |
| FY2023 | Dec 31, 2023 | -$17.13M | – |
| FY2022 | Dec 31, 2022 | -$34.46M | – |
| FY2021 | Dec 31, 2021 | -$26.56M | – |
| FY2020 | Dec 31, 2020 | -$8.32M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.69M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.13M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.24M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.84M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.31M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.46M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.74M | – |
See a number that looks wrong?